Comparison of Systemic and Mucosal Delivery of 2 Canarypox Virus Vaccines Expressing either HIV‐1 Genes or the Gene for Rabies Virus G Protein

Abstract

Background. Since the primary routes of human immunodeficiency type 1 (HIV-1) infection are across mucosal barriers, a randomized trial of canarypox virus-based vectors was conducted in 84 individuals, with delivery of vaccine by mucosal routes, and was accompanied by a detailed analysis of humoral, cellular, and mucosal immune responses.